Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 82

1.

Aquaporin-4 antibodies in patients treated with natalizumab for suspected MS.

Gahlen A, Trampe AK, Haupeltshofer S, Ringelstein M, Aktas O, Berthele A, Wildemann B, Gold R, Jarius S, Kleiter I.

Neurol Neuroimmunol Neuroinflamm. 2017 Jun 16;4(4):e363. doi: 10.1212/NXI.0000000000000363. eCollection 2017 Jul.

2.

Expanding Role of T Cells in Human Autoimmune Diseases of the Central Nervous System.

Pilli D, Zou A, Tea F, Dale RC, Brilot F.

Front Immunol. 2017 Jun 7;8:652. doi: 10.3389/fimmu.2017.00652. eCollection 2017. Review.

3.

Update on neuromyelitis optica: natural history and management.

Jindahra P, Plant T.

Eye Brain. 2012 Mar 26;4:27-41. doi: 10.2147/EB.S8392. eCollection 2012. Review.

4.

Adaptive Immunity Is the Key to the Understanding of Autoimmune and Paraneoplastic Inflammatory Central Nervous System Disorders.

Weissert R.

Front Immunol. 2017 Mar 23;8:336. doi: 10.3389/fimmu.2017.00336. eCollection 2017. Review.

5.

Rituximab therapy in pemphigus and other autoantibody-mediated diseases.

Ran NA, Payne AS.

F1000Res. 2017 Jan 27;6:83. doi: 10.12688/f1000research.9476.1. eCollection 2017. Review.

6.

Aquaporin-4 antibody titration in NMO patients treated with rituximab: A retrospective study.

Valentino P, Marnetto F, Granieri L, Capobianco M, Bertolotto A.

Neurol Neuroimmunol Neuroinflamm. 2016 Dec 15;4(2):e317. doi: 10.1212/NXI.0000000000000317. eCollection 2017 Mar.

7.

Antibodies from multiple sclerosis patients preferentially recognize hyperglucosylated adhesin of non-typeable Haemophilus influenzae.

Walvoort MT, Testa C, Eilam R, Aharoni R, Nuti F, Rossi G, Real-Fernandez F, Lanzillo R, Brescia Morra V, Lolli F, Rovero P, Imperiali B, Papini AM.

Sci Rep. 2016 Dec 23;6:39430. doi: 10.1038/srep39430.

8.
9.

Evaluation of aquaporin-4 antibody assays.

Waters PJ, Pittock SJ, Bennett JL, Jarius S, Weinshenker BG, Wingerchuk DM.

Clin Exp Neuroimmunol. 2014 Oct;5(3):290-303. Epub 2014 Apr 22.

10.

MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome.

Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K, Pache F, Stich O, Beume LA, Hümmert MW, Ringelstein M, Trebst C, Winkelmann A, Schwarz A, Buttmann M, Zimmermann H, Kuchling J, Franciotta D, Capobianco M, Siebert E, Lukas C, Korporal-Kuhnke M, Haas J, Fechner K, Brandt AU, Schanda K, Aktas O, Paul F, Reindl M, Wildemann B; in cooperation with the Neuromyelitis Optica Study Group (NEMOS).

J Neuroinflammation. 2016 Sep 27;13(1):280.

11.

MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin.

Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, Pitarokoili K, Pache F, Stich O, Beume LA, Hümmert MW, Trebst C, Ringelstein M, Aktas O, Winkelmann A, Buttmann M, Schwarz A, Zimmermann H, Brandt AU, Franciotta D, Capobianco M, Kuchling J, Haas J, Korporal-Kuhnke M, Lillevang ST, Fechner K, Schanda K, Paul F, Wildemann B, Reindl M; in cooperation with the Neuromyelitis Optica Study Group (NEMOS).

J Neuroinflammation. 2016 Sep 26;13(1):279.

12.

Circulating microRNAs as biomarkers for rituximab therapy, in neuromyelitis optica (NMO).

Vaknin-Dembinsky A, Charbit H, Brill L, Abramsky O, Gur-Wahnon D, Ben-Dov IZ, Lavon I.

J Neuroinflammation. 2016 Jul 8;13(1):179. doi: 10.1186/s12974-016-0648-x.

13.

Loss of Myelin Basic Protein Function Triggers Myelin Breakdown in Models of Demyelinating Diseases.

Weil MT, Möbius W, Winkler A, Ruhwedel T, Wrzos C, Romanelli E, Bennett JL, Enz L, Goebels N, Nave KA, Kerschensteiner M, Schaeren-Wiemers N, Stadelmann C, Simons M.

Cell Rep. 2016 Jul 12;16(2):314-22. doi: 10.1016/j.celrep.2016.06.008. Epub 2016 Jun 23.

14.

An update on the evidence for the efficacy and safety of rituximab in the management of neuromyelitis optica.

Collongues N, de Seze J.

Ther Adv Neurol Disord. 2016 May;9(3):180-8. doi: 10.1177/1756285616632653. Epub 2016 Mar 23. Review.

15.

The Immunology of Neuromyelitis Optica-Current Knowledge, Clinical Implications, Controversies and Future Perspectives.

Jasiak-Zatonska M, Kalinowska-Lyszczarz A, Michalak S, Kozubski W.

Int J Mol Sci. 2016 Mar 2;17(3):273. doi: 10.3390/ijms17030273. Review.

16.

Rituximab monitoring and redosing in pediatric neuromyelitis optica spectrum disorder.

Nosadini M, Alper G, Riney CJ, Benson LA, Mohammad SS, Ramanathan S, Nolan M, Appleton R, Leventer RJ, Deiva K, Brilot F, Gorman MP, Waldman AT, Banwell B, Dale RC.

Neurol Neuroimmunol Neuroinflamm. 2016 Jan 21;3(1):e188. doi: 10.1212/NXI.0000000000000188. eCollection 2016 Feb.

17.

Present and Future Therapies in Neuromyelitis Optica Spectrum Disorders.

Kleiter I, Gold R.

Neurotherapeutics. 2016 Jan;13(1):70-83. doi: 10.1007/s13311-015-0400-8. Review.

18.

The Urine Proteome Profile Is Different in Neuromyelitis Optica Compared to Multiple Sclerosis: A Clinical Proteome Study.

Nielsen HH, Beck HC, Kristensen LP, Burton M, Csepany T, Simo M, Dioszeghy P, Sejbaek T, Grebing M, Heegaard NH, Illes Z.

PLoS One. 2015 Oct 13;10(10):e0139659. doi: 10.1371/journal.pone.0139659. eCollection 2015.

19.

Acute and Chronic Management of Neuromyelitis Optica Spectrum Disorder.

Sherman E, Han MH.

Curr Treat Options Neurol. 2015 Nov;17(11):48. doi: 10.1007/s11940-015-0378-x.

20.

Update on biomarkers in neuromyelitis optica.

Melamed E, Levy M, Waters PJ, Sato DK, Bennett JL, John GR, Hooper DC, Saiz A, Bar-Or A, Kim HJ, Pandit L, Leite MI, Asgari N, Kissani N, Hintzen R, Marignier R, Jarius S, Marcelletti J, Smith TJ, Yeaman MR, Han MH, Aktas O, Apiwattanakul M, Banwell B, Bichuetti D, Broadley S, Cabre P, Chitnis T, De Seze J, Fujihara K, Greenberg B, Hellwig K, Iorio R, Jarius S, Klawiter E, Kleiter I, Lana-Peixoto M, Nakashima, O'Connor K, Palace J, Paul F, Prayoonwiwat N, Ruprecht K, Stuve O, Tedder T, Tenembaum S, Garrahan JP, Aires B, van Herle K, van Pelt D, Villoslada P, Waubant E, Weinshenker B, Wingerchuk D, Würfel J, Zamvil S.

Neurol Neuroimmunol Neuroinflamm. 2015 Jul 23;2(4):e134. doi: 10.1212/NXI.0000000000000134. eCollection 2015 Aug. Review.

Supplemental Content

Support Center